Hey {{first_name|default:there}}, it’s Vadim 👋
I’ll be honest - I’m writing this from a family vacation and had something entirely different planned for yesterday’s issue.
But then I got word of Anthropic's $400M acquisition of Coefficient Bio - a company reportedly around for less than 8 months, with 10 people, and no reported product or revenue.
I've written previously about what I thought of Anthropic and OpenAI strategy in life sciences and healthcare after JPM, but this added a whole new perspective.
It also made me reflect about where this industry is actually heading, and what it means for so many of you who are building across adjacent spaces.
So, I went down the rabbit hole. Which means that today, we’ll be taking a break from our usual format and doing a full teardown of this deal.
🧭 HERE’S WHAT WE’LL COVER:
Full deal teardown - why Coefficient Bio and why now
The three competing strategies for owning AI + biology from Google, OpenAI and Anthropic
Anthropic’s life sciences strategy today and it’s north star over the next several years
What could go wrong in a deal like this
And most importantly, what this deal means for you if you’re a founder in this space
Let’s dive in!